File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Cyclosporine-to-tacrolimus conversion compared with cyclosporine minimization on allograft function and TGF-β1/HGF levels in chronic renal allograft nephropathy

TitleCyclosporine-to-tacrolimus conversion compared with cyclosporine minimization on allograft function and TGF-β1/HGF levels in chronic renal allograft nephropathy
Authors
Issue Date2006
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
Citation
World Transplant Congress 2006, Boston, MA, 22 - 27 July 2006. In American Journal of Transplantation, 2006, v. 6 n. S2, p. 508 Abstract no. 1308 How to Cite?
AbstractBackground. Tacrolimus and cyclosporine might have different effects onintra-renal fibrosis and allograft function in chronic renal allograftnephropathy (CAN). It is difficult to predict the response to calcineurininhibitor minimization in patients with CAN.Methods. This prospective randomized study compared cyclosporine A(CsA)-to-tacrolimus conversion (Group A, target tacrolimus trough level6-8 ng/mL) versus CsA minimization (Group B, target CsA trough level 80-100 ng/mL) with regard to efficacy, safety, and effect on growth factorlevels in patients with CAN and deteriorating allograft function. Theprimary efficacy endpoint was improvement in the slope of inverse serumcreatinine (sCr)-against-time plot. Circulating levels of TGF-β1, HGF,BMP-7, VEGF and fibronectin were measured serially in 16 patients.Results. 34 patients were included. 9 (56.3%) subjects in Group A (n=16)and 10 (55.6%) in Group B (n=18) reached the primary endpoint (P=0.968).Group A showed significantly improved 1/sCr-against-time slope followingintervention (P=0.029), while between-group difference was insignificantbefore and after intervention. 9 of 16 patients (56.3%) showed ≥50%TGF-β1 reduction or HGF increase after intervention, amongst whom 8(88.9%) also showed an improvement in 1/sCr-against-time slope. Acuterejection occurred in 2 patients (Group A). Blood glucose, lipids, and bloodpressure did not change significantly, and did not differ between groups.Conclusions. In patients with CAN CsA-to-tacrolimus conversion and CsAminimization targeting low blood levels are both effective in reducing therate of renal function deterioration in over half of the patients, and thisrenal preservation response is accompanied by improvements in TGF-β1and/or HGF.
Persistent Identifierhttp://hdl.handle.net/10722/102139
ISSN
2015 Impact Factor: 5.669
2015 SCImago Journal Rankings: 2.792

 

DC FieldValueLanguage
dc.contributor.authorTang, SCWen_HK
dc.contributor.authorYung, Sen_HK
dc.contributor.authorTang, CSOen_HK
dc.contributor.authorLam, MFen_HK
dc.contributor.authorTsang, RCWen_HK
dc.contributor.authorTse, KCen_HK
dc.contributor.authorLai, KNen_HK
dc.contributor.authorHo YWen_HK
dc.contributor.authorTong, MKL-
dc.contributor.authorChan, DTM-
dc.date.accessioned2010-09-25T20:18:37Z-
dc.date.available2010-09-25T20:18:37Z-
dc.date.issued2006en_HK
dc.identifier.citationWorld Transplant Congress 2006, Boston, MA, 22 - 27 July 2006. In American Journal of Transplantation, 2006, v. 6 n. S2, p. 508 Abstract no. 1308en_HK
dc.identifier.issn1600-6135en_HK
dc.identifier.urihttp://hdl.handle.net/10722/102139-
dc.description.abstractBackground. Tacrolimus and cyclosporine might have different effects onintra-renal fibrosis and allograft function in chronic renal allograftnephropathy (CAN). It is difficult to predict the response to calcineurininhibitor minimization in patients with CAN.Methods. This prospective randomized study compared cyclosporine A(CsA)-to-tacrolimus conversion (Group A, target tacrolimus trough level6-8 ng/mL) versus CsA minimization (Group B, target CsA trough level 80-100 ng/mL) with regard to efficacy, safety, and effect on growth factorlevels in patients with CAN and deteriorating allograft function. Theprimary efficacy endpoint was improvement in the slope of inverse serumcreatinine (sCr)-against-time plot. Circulating levels of TGF-β1, HGF,BMP-7, VEGF and fibronectin were measured serially in 16 patients.Results. 34 patients were included. 9 (56.3%) subjects in Group A (n=16)and 10 (55.6%) in Group B (n=18) reached the primary endpoint (P=0.968).Group A showed significantly improved 1/sCr-against-time slope followingintervention (P=0.029), while between-group difference was insignificantbefore and after intervention. 9 of 16 patients (56.3%) showed ≥50%TGF-β1 reduction or HGF increase after intervention, amongst whom 8(88.9%) also showed an improvement in 1/sCr-against-time slope. Acuterejection occurred in 2 patients (Group A). Blood glucose, lipids, and bloodpressure did not change significantly, and did not differ between groups.Conclusions. In patients with CAN CsA-to-tacrolimus conversion and CsAminimization targeting low blood levels are both effective in reducing therate of renal function deterioration in over half of the patients, and thisrenal preservation response is accompanied by improvements in TGF-β1and/or HGF.-
dc.languageengen_HK
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJTen_HK
dc.relation.ispartofAmerican Journal of Transplantationen_HK
dc.titleCyclosporine-to-tacrolimus conversion compared with cyclosporine minimization on allograft function and TGF-β1/HGF levels in chronic renal allograft nephropathyen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1600-6135&volume=Suppl&spage=508&epage=&date=2006&atitle=Cyclosporine-to-tacrolimus+conversion+compared+with+cyclosporine+minimization+on+allograft+function+and+TGF-β1/HGF+levels+in+chronic+renal+allograft+nephropathyen_HK
dc.identifier.emailTang, SCW: scwtang@hku.hken_HK
dc.identifier.emailTang, CSO: csotang@HKUCC.hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.emailChan, DTM: dtmchan@hku.hken_HK
dc.identifier.authorityTang, SCW=rp00480en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.authorityChan, DTM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1600-6143.2006.01447.x-
dc.identifier.hkuros136813en_HK
dc.identifier.volumeSupplen_HK
dc.identifier.spage508en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats